Eli Lilly's oral drug muvalaplin showed significant reductions in lipoprotein(a) levels in a Phase 2 trial of 233 high-risk ...

Johnson & Johnson and Protagonist Therapeutics announced two Phase 3 successes for their oral IL-23 drug, showcasing the ...

T cell therapy for autoimmune diseases, showing clinical responses in seven lupus patients. The therapy uses the same ...

They've got $70 million, two guys named Ned, and plans to go after early-stage science where other venture capital firms ...

Efforts by the pharmaceutical industry to expand access to low-and-middle-income countries need to be “vastly accelerated” ...

Incyte’s $750 million buyout of Escient Pharmaceuticals is in a rough patch as a mid-stage chronic hives candidate was ...

Synapticure, a startup building digital health tools for people with neurodegenerative conditions and their caregivers, has ...

Therapists can’t be around for their patients 24/7. One startup is betting AI can be the solution. When trained with clinical ...

Biogen and UCB on Tuesday shared an expanded dataset for their Phase 3 lupus program, which they said two months ago ...

New hepatitis D treatment data from Vir Biotechnology and Bluejay Therapeutics shows promising results in reducing viral levels. Both companies plan further trials, with Vir targeting Phase 3 in 2025.

Rocket Pharmaceuticals reported Monday that benefits from its Danon disease gene therapy were seen up to around five years after treatment.

CSL Behring is closing its Pasadena R&D site, relocating operations to Waltham, Massachusetts, affecting 30 employees. The company is deprioritizing ex vivo lentiviral gene therapy work and focusing ...